Shandong Xinhua Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

6.21

P/S

0.38

EPS

0.88

Div Yield, %

4.11%

Shrs. gr., 5y

2.06%

Rev. gr., 5y

9.24%

Revenues

8.10b

+7.97%

Net income

497m

+20.79%

CFO

265m

-65.01%

Dividend

Sep 04, 20240.027289 HKD/sh

Profile

Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical bulk drugs, Preparations, and Chemical intermediates and Others segments. The company offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for diseases related to the central nervous system; and other drugs under the Xinhua brand. It also provides prepared Chinese herbal medicine decoction, traditional Chinese medicines, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc.; and chemical raw materials, such as dimethyl sulfate, isobutylbenzene, 1,8-diazabicyclo, undec-7-ene, and tetramethylguanidine. In addition, the company offers materials and intermediates, powders for injection and tablets; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; and health products research and development activities. Further, it engages in the certification business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as the sale of mechanical, hardware, and electrical equipment. Additionally, the company produces and sells high-end steroid system APIs and intermediates; and provides internet data, internet sells, and internet information services for pharmaceuticals and medical devices, etc. It operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.

URL

http://www.xhzy.com/

IPO date

Dec 31, 1996

Employees

6,839

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	8,100,845 7.97%	7,502,987 14.37%	6,560,078 9.23%
Cost of revenue	6,956,059	6,626,173	5,816,668
Unusual Expense (Income)
NOPBT	1,144,786	876,814	743,410
NOPBT Margin	14.13%	11.69%	11.33%
Operating Taxes	26,579	45,460	59,159
Tax Rate	2.32%	5.18%	7.96%
NOPAT	1,118,207	831,355	684,251
Net income	496,512 20.79%	411,063 17.94%	348,548 7.29%
Dividends	(134,937)	(100,444)	(94,105)
Dividend yield	0.96%	0.50%	1.35%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	1,073,177	835,485	693,280
Long-term debt	802,558	551,087	354,755
Deferred revenue		118,373	132,164
Other long-term liabilities	223,434	23,562	630,763
Net debt	716,031	(59,708)	(13,132)
Cash flow
Cash from operating activities	265,279	758,241	259,117
CAPEX	(325,133)
Cash from investing activities	(305,109)
Cash from financing activities	(196,110)
FCF	34,281	797,309	329,782
Balance
Cash	918,334	1,158,742	744,662
Long term investments	241,369	287,538	316,504
Excess cash	754,661	1,071,130	733,163
Stockholders' equity	3,319,782	3,625,803	3,166,752
Invested Capital	6,118,681	4,770,848	4,696,420
ROIC	20.54%	17.56%	15.20%
ROCE	16.66%	14.84%	13.53%
EV
Common stock shares outstanding	689,600	673,874	622,408
Price	20.38 -32.29%	30.10 168.99%	11.19 19.30%
Market cap	14,054,054 -30.71%	20,283,603 191.23%	6,964,746 19.40%
EV	14,992,734	20,447,340	7,134,817
EBITDA	1,665,041	1,361,621	1,177,739
EV/EBITDA	9.00	15.02	6.06
Interest	44,072	49,707	53,103
Interest/NOPBT	3.85%	5.67%	7.14%